hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06329505, orgStudyIdInfo id: 111-085-B, briefTitle: Impact of Extracorporeal Membrane Oxygenation Care Strategy Application Development, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Pei-Hung Liao, class: OTHER, descriptionModule briefSummary: The objective of this study was to develop an educational training App for ECMO care, and to apply a blended learning approach to improve the knowledge and skills of nurses., conditionsModule conditions: Learning Problem, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, outcomesModule primaryOutcomes measure: Comparison of knowledge and skills of nurses between groups after the intervention For 6 months., eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: National Taipei university of nursing and health science, city: Taipei, country: Taiwan, geoPoint lat: 25.04776, lon: 121.53185, hasResults: False
protocolSection identificationModule nctId: NCT06329492, orgStudyIdInfo id: 23-007937, briefTitle: Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis, acronym: A2MRP, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-01-09, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: The purpose of this study is to determine the effectiveness and safety of autologous alpha-2 macroglobulin rich plasma (A2MRP) injections in the treatment of knee osteoarthritis (OA)., conditionsModule conditions: Osteoarthritis, conditions: OA, conditions: Knee Osteoarthritis, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Single group cohort of 20 subjects, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP), outcomesModule primaryOutcomes measure: Adverse Events, secondaryOutcomes measure: Visual Analog Scale (VAS) for Pain, secondaryOutcomes measure: Patient-Reported Outcomes Measurement Information System (PROMIS)-Computer adaptive test (CAT): Pain interference, secondaryOutcomes measure: Patient-Reported Outcomes Measurement Information System (PROMIS)-Computer adaptive test (CAT): Physical function, secondaryOutcomes measure: Knee Injury and Osteoarthritis Outcome Score (KOOS):, secondaryOutcomes measure: Procedure Recommendation, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic, city: Rochester, state: Minnesota, zip: 55905, country: United States, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06329479, orgStudyIdInfo id: 1926B, briefTitle: A Feasibility Trial for Circadian Rest-activity Rhythm Disorders in Cancer (RALI), statusModule overallStatus: RECRUITING, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-09-01, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: University of Dublin, Trinity College, class: OTHER, descriptionModule briefSummary: Circadian rest-activity rhythm disorders are common in patients with cancer, particularly in advanced disease. A recent international e-Delphi study has outlined recommendations for the assessment and reporting of the disorder and subsequently an observation study is underway assessing a cohort of patients with advanced cancer. Affected patients are eligible to enter a feasibility study assessing a non-pharmacological multi-modal intervention., conditionsModule conditions: Circadian Rhythm Disorders, conditions: Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Cognitive behavioural therapy for Insomnia (CBT-I), interventions name: Bright Light Therapy, interventions name: Individualised activity plan, interventions name: Clincial review, outcomesModule primaryOutcomes measure: Acceptability and usability of a multi-modal non-pharmacological intervention, primaryOutcomes measure: Adherence to interventions, primaryOutcomes measure: Adverse events, primaryOutcomes measure: Completion rates of research assessments, primaryOutcomes measure: Recruitment rate, secondaryOutcomes measure: Symptom assessment, secondaryOutcomes measure: Quality of Life assessment, secondaryOutcomes measure: Daytime Sleepiness, secondaryOutcomes measure: Sleep Quality, secondaryOutcomes measure: Physical activity assessment, secondaryOutcomes measure: Physical activity and sleep assessment, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Our Lady's Hospice & Care Services, status: RECRUITING, city: Dublin, zip: D6W RY72, country: Ireland, contacts name: Craig Gouldthorpe, role: CONTACT, phone: +3534986235, email: gouldthc@tcd.ie, geoPoint lat: 53.33306, lon: -6.24889, locations facility: St James's Hospital, status: RECRUITING, city: Dublin, zip: D6W RY72, country: Ireland, contacts name: Craig Gouldthorpe, role: CONTACT, phone: +3534986235, email: gouldthc@tcd.ie, geoPoint lat: 53.33306, lon: -6.24889, hasResults: False
protocolSection identificationModule nctId: NCT06329453, orgStudyIdInfo id: 2000033081, briefTitle: Intestinal Immunity in Neurologic Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-08-02, primaryCompletionDateStruct date: 2027-08-31, completionDateStruct date: 2027-08-31, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: Yale University, class: OTHER, descriptionModule briefSummary: The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases., conditionsModule conditions: Multiple Sclerosis, conditions: Parkinson Disease, conditions: REM Sleep Behavior Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Colon Tissue Biopsy, outcomesModule primaryOutcomes measure: Characterization of immune cells from the gastrointestinal mucosa, secondaryOutcomes measure: Evaluate spatial transcriptomics of intestinal tissue, secondaryOutcomes measure: Characterize the microbiome at different anatomic sites within the gastrointestinal tract, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Yale MS Clinic, status: RECRUITING, city: North Haven, state: Connecticut, zip: 06473, country: United States, contacts name: Cynthia Marques, role: CONTACT, phone: 203-287-6100, email: cynthia.marques@yale.edu, contacts name: Dimitri Duvilaire, role: CONTACT, phone: 2032876100, email: dimitri.duvilaire@yale.edu, contacts name: Erin Longbrake, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.39093, lon: -72.85954, hasResults: False
protocolSection identificationModule nctId: NCT06329440, orgStudyIdInfo id: 2023/880, briefTitle: Comparison of Supraclavicular and Costoclavicular Brachial Plexus Blocks in Adult Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-10-05, studyFirstPostDateStruct date: 2024-03-26, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Istanbul University, class: OTHER, descriptionModule briefSummary: Hemidiaphragmatic paresis is a common side effect of brachial plexus blocks such as supraclavicular or infraclavicular block techniques. It has been shown that diaphragma thickness is affected at some extent in supraclavicular block and also in costoclavicular block which is accepted as an infraclavicular approach. However, these two approaches have not been extensively investigated before in terms of the diaphragmatic paresis. Here, it is aimed to compare these two methods considering their effects on diaphragma thickness in inspirium and in expirium. Moreover, the performance properties such as motor and sensory block onset, needle visualization time, needle visualization difficulty, postoperative pain scores, and lastly the perfusion index which is known to be reflecting vasodilation will be investigated., conditionsModule conditions: Diaphragm Injury, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: DOUBLE, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasonographic measurement of diaphragm thickness, outcomesModule primaryOutcomes measure: Diaphragm thickness fraction (centimeters), secondaryOutcomes measure: Diaphragm thickness at the end of expirium (centimeters)., secondaryOutcomes measure: Diaphragm thickness at the end of inspirium (centimeters)., secondaryOutcomes measure: Perfusion index change, secondaryOutcomes measure: Motor and sensory block onset time, secondaryOutcomes measure: Postoperative pain scores (0-10), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istanbul University Istanbul Faculty of Medicine, status: RECRUITING, city: Istanbul, country: Turkey, contacts name: Meltem Savran Karadeniz, MD, Assoc Prof, role: CONTACT, email: mskaradeniz@gmail.com, contacts name: Ozgur Selek, MD, role: CONTACT, phone: 00905057883600, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06329414, orgStudyIdInfo id: 00164631, briefTitle: Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-16, primaryCompletionDateStruct date: 2026-01, completionDateStruct date: 2026-01, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: University of Utah, class: OTHER, descriptionModule briefSummary: The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS. Participants will receive outpatient TMS treatment over the course of 5-6 weeks. Participants will complete validated questionnaires and exams before, during, and after treatment., conditionsModule conditions: Multiple Sclerosis, conditions: Major Depressive Disorder, conditions: Treatment Resistant Depression, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 12, type: ESTIMATED, outcomesModule primaryOutcomes measure: Feasibility of TMS treatment for MDD, per participant retention rates., primaryOutcomes measure: Safety and tolerability, to be evaluated by side effects and adverse events over the course of treatment., secondaryOutcomes measure: Depression response rates (50% reduction in symptoms) will be measured using MADRS scores before and after treatment., secondaryOutcomes measure: Depression remission rates will be measured using MADRS scores before and after treatment., secondaryOutcomes measure: MS lesion burden on MRI will be compared before and after treatment to determine impact of TMS on white matter disease burden., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Utah Health, status: RECRUITING, city: Salt Lake City, state: Utah, zip: 84108, country: United States, contacts name: Kathleen Shangraw, MD, role: CONTACT, phone: 801-583-2500, geoPoint lat: 40.76078, lon: -111.89105, hasResults: False
protocolSection identificationModule nctId: NCT06329388, orgStudyIdInfo id: CSD-SFRI-013, briefTitle: Evaluating the Effects of an Oral Protein Supplement on Children's Growth Patterns, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-18, primaryCompletionDateStruct date: 2023-07-07, completionDateStruct date: 2023-08-11, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: TruHeight Vitamins, class: INDUSTRY, collaborators name: San Francisco Research Institute, descriptionModule briefSummary: This single-center, randomized controlled pilot study aims to evaluate the efficacy of TruHeight Growth Protein Shake on improving growth patterns in children aged 4-17 years. Over six months, participants will consume the protein shake daily, five times a week, with outcomes measured in terms of type X collagen concentration in urine, height via a stadiometer, and body composition using an INBODY device., conditionsModule conditions: Growth Disorders, conditions: Dietary Exposure, conditions: Child Development, conditions: Bone Development Abnormal, conditions: Body Weight, conditions: Child Malnutrition, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized Controlled Trial (RCT) with two parallel groups (treatment and control group)., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 32, type: ACTUAL, armsInterventionsModule interventions name: TruHeight Growth Protein Shake, outcomesModule primaryOutcomes measure: Change in Height, secondaryOutcomes measure: Change in Type X Collagen Concentration in Urine, secondaryOutcomes measure: Change in Body Composition, secondaryOutcomes measure: Incidence of Adverse Events, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: SF Research Institute, city: San Francisco, state: California, zip: 94127, country: United States, geoPoint lat: 37.77493, lon: -122.41942, hasResults: False
protocolSection identificationModule nctId: NCT06329375, orgStudyIdInfo id: 72967, briefTitle: Food Insecurity Reduction & Strategy Team, acronym: FIRST, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-02-05, completionDateStruct date: 2025-02-05, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, descriptionModule briefSummary: This study seeks to address the multifaceted challenges posed by food disparities and their negative consequences on health outcomes, via a comprehensive community health intervention program. Study objectives include:1. To describe the social-demographic and clinical factors associated with food insecurity in the hospitalized diabetic population.2. To design, implement and evaluate a nutrition program targeting the hospitalized diabetic population. The investigators will prospectively randomize the target population into either a nutrition program (Intervention), or state-of-art standard of care (SOC) in a 4:1 ratio. Participants in the intervention group will be provided the following two resources in addition to SOC: 1) Enhanced access to nutritious food (twice daily meal delivery up to 90 days post-discharge) 2) Education at discharge and continuing outreach to enhance knowledge for better diet and food options.3. To enhance community engagement and develop a systematic implementation plan for long-term roll-out of the nutrition program., conditionsModule conditions: Diabetes Mellitus, Type 2, conditions: Food Insecurity, conditions: Diabetes Mellitus, Type 1, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants will be prospectively randomized into either a nutrition program (intervention), or receiving state-of-the-art standard of care (SOC) in a 4:1 ratio. Patients in the intervention group will be provided the following two resources in addition to SOC:1. Enhanced access to nutritious food (twice daily meal delivery up to 90 days post-discharge),2. Education at discharge and continuing outreach to enhance knowledge for better diet and food options, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 160, type: ESTIMATED, armsInterventionsModule interventions name: Nutrition program, outcomesModule primaryOutcomes measure: Food insecurity at 30-days post initial discharge, secondaryOutcomes measure: Food insecurity at 60- and 90- days post post initial discharge, secondaryOutcomes measure: Measures of diabetes stress, secondaryOutcomes measure: Measures of hypoglycemia, secondaryOutcomes measure: Measures of medication adherence, secondaryOutcomes measure: Hospitalization, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06329362, orgStudyIdInfo id: 2-7-23, briefTitle: Minimally Invasive Ridge Splitting Versus the Conventional Open Flap Technique, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-31, primaryCompletionDateStruct date: 2025-07, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-26, sponsorCollaboratorsModule leadSponsor name: The Royal College of Surgeons of Edinburgh, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare implant stability, and crestal bone loss, when using minimal invasive ridge splitting versus convenient open flap technique. The main question is Does Minimal Invasive Implant ridge splitting ("transmucosal" without flap) influence the implant stability and crystal bone loss, when compared with the conventional open flap techniques? Researchers will compare Group A: Minimal Invasive Implant ridge splitting and Group B: Triangular flap technique is used to see if there is significant difference between the two groups when measuring implant stability, and crestal bone density., conditionsModule conditions: Alveolar Bone Loss, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 16, type: ESTIMATED, armsInterventionsModule interventions name: Minimally invasive implantation, interventions name: Open flap procedure for ridge expansion., outcomesModule primaryOutcomes measure: Implant stability., primaryOutcomes measure: CBCT assessment, secondaryOutcomes measure: Postoperative Pain, secondaryOutcomes measure: Operation Time, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of Dentistry Cairo University, status: RECRUITING, city: Cairo, zip: 35855, country: Egypt, contacts name: Bassem Emad, MDs, role: CONTACT, phone: +201001113474, email: bassem_26@hotmail.com, contacts name: Emad Deif, Prof, role: CONTACT, phone: +201222331938, email: daif_emad@yahoo.com, geoPoint lat: 30.06263, lon: 31.24967, locations facility: Future Dental Academy GmbH, status: RECRUITING, city: Flonheim, state: Rheinland - Pfalz, zip: D-55237, country: Germany, contacts name: Armin Nadjet, A.Prof, role: CONTACT, phone: +4915115253692, email: nedjat@t-online.de, contacts name: Rainer Zoppke, role: CONTACT, phone: +491778339601, email: Rainer.Zoppke@champions-implants.com, geoPoint lat: 49.785, lon: 8.04, hasResults: False
protocolSection identificationModule nctId: NCT06329310, orgStudyIdInfo id: XEL-CR-14, briefTitle: Xeltis Hemodialysis Access Conduit: aXess-E Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-03-25, lastUpdatePostDateStruct date: 2024-03-25, sponsorCollaboratorsModule leadSponsor name: Xeltis, class: INDUSTRY, descriptionModule briefSummary: A prospective, single arm, non-randomized feasibility study to confirm the safety and performance of the Xeltis Hemodialysis Access conduit, aXess-E, in subjects older than 18 years with end-stage renal disease, who plan to undergo hemodialysis for at least the first 6 months after study access creation., conditionsModule conditions: End Stage Renal Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: aXess-E conduit, outcomesModule primaryOutcomes measure: Primary Patency rate, primaryOutcomes measure: Freedom from device-related SAE, secondaryOutcomes measure: Implantation success rate, secondaryOutcomes measure: Primary patency rate, secondaryOutcomes measure: Primary assisted patency rate, secondaryOutcomes measure: Secondary patency rate, secondaryOutcomes measure: Functional patency rate, secondaryOutcomes measure: Time (expressed in months) to first intervention and to access abandonment, secondaryOutcomes measure: Rate of access-related interventions required to achieve/maintain patency, secondaryOutcomes measure: Freedom from device-related SAE, secondaryOutcomes measure: Rate of access site infections, secondaryOutcomes measure: Proportion of hemodialysis sessions completed via central venous catheter (CVC) during the first 12 months of access creation and access cannulation, irrespective of access abandonment, secondaryOutcomes measure: Time to first cannulation, secondaryOutcomes measure: Following first cannulation, number of days with CVC in situ (catheter contact time) irrespective of access abandonment, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False